for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Compugen Ltd. (USA)

CGEN.OQ

Latest Trade

5.60USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.00

 - 

6.22

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Compugen Reports Q3 Loss Per Share Of $0.10

Nov 11 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN REPORTS THIRD QUARTER 2019 RESULTS.Q3 LOSS PER SHARE $0.10.AS OF SEPTEMBER 30, 2019, CASH, CASH EQUIVALENTS, SHORT-TERM BANK DEPOSITS AND RESTRICTED CASH TOTALED $47.6 MILLION.

Compugen Presents Initial Clinical Data From Ongoing Phase 1 Trial Of Com701 In Patients With Advanced Solid Tumors At Sitc 2019

Nov 5 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN PRESENTS INITIAL CLINICAL DATA FROM ONGOING PHASE 1 TRIAL OF COM701 IN PATIENTS WITH ADVANCED SOLID TUMORS AT SITC 2019.COMPUGEN LTD - COM701 WAS WELL-TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED.COMPUGEN LTD - INITIAL SIGNALS OF ANTI-TUMOR ACTIVITY OBSERVED IN HEAVILY PRETREATED PATIENT POPULATION IN DOSE ESCALATION ARM OF STUDY.

Compugen Announces FDA Clearance Of Ind Application For Com902

Nov 4 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR COM902.COMPUGEN- UNDER IND, INTENDS TO INITIATE A PHASE 1 CLINICAL TRIAL IN PATIENTS WITH ADVANCED MALIGNANCIES.COMPUGEN LTD - PHASE 1 CLINICAL STUDY IN PATIENTS WITH ADVANCED MALIGNANCIES EXPECTED TO BEGIN IN EARLY 2020.

Compugen Ltd Files For Mixed Shelf Of Upto $200 Million

Aug 5 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN LTD FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.

Compugen Q2 Loss Per Share $0.10

Compugen Ltd <CGEN.TA>::COMPUGEN REPORTS SECOND QUARTER 2019 RESULTS.Q2 LOSS PER SHARE $0.10.AS OF JUNE 30, 2019, CASH, CASH RELATED ACCOUNTS, SHORT-TERM AND LONG-TERM BANK DEPOSITS TOTALED $37.0 MILLION.

Compugen Reports Qtrly Loss Per Share $0.14

May 20 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN REPORTS FIRST QUARTER 2019 RESULTS.COMPUGEN LTD - QTRLY LOSS PER SHARE $0.14.

Compugen Issues 2 U.S. Composition Of Matter Patents For COM701, Its Immuno-Oncology Product Candidate

March 12 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN ANNOUNCES ISSUANCE OF TWO U.S. COMPOSITION OF MATTER PATENTS FOR COM701, ITS LEAD IMMUNO-ONCOLOGY PRODUCT CANDIDATE.COMPUGEN - PATENT WHICH COVERS COMPOSITION COMPRISING COM701 AND BACKUP ANTIBODIES, IS EXPECTED TO EXPIRE NO EARLIER THAN AUGUST 2037 IN UNITED STATES.

Compugen Posts Q4 Loss Per Share $0.16

Feb 26 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS AND ANNOUNCES CORPORATE RESTRUCTURING TO STREAMLINE OPERATIONS.Q4 LOSS PER SHARE $0.16.RESTRUCTURING INCLUDES CONSOLIDATION OF RESEARCH AND DEVELOPMENT ACTIVITIES IN ONE LOCATION (ISRAEL).POSITIONS AND OPERATIONS ELIMINATED WILL ALSO REDUCE OVERLAPPING RESEARCH AND DEVELOPMENT AND G&A ACTIVITIES IN ISRAEL AND UNITED STATES.RESTRUCTURING INCLUDES A 35% WORKFORCE REDUCTION (APPROXIMATELY 35 EMPLOYEES), MAJORITY OF WHICH IS IN RESEARCH AND DEVELOPMENT.CERTAIN PRECLINICAL ACTIVITIES WILL BE OUTSOURCED TO THIRD-PARTY SERVICE PROVIDERS.COMPUGEN ANTICIPATES SAVINGS OF UP TO $10 MILLION ON AN ANNUAL BASIS.BASED ON CURRENT CASH,ANTICIPATED SAVINGS RESULTING FROM RESTRUCTURING ACTIVITIES, CO EXPECTS CASH RUNWAY TO EXTEND THROUGH MID-2020.COMPUGEN -SEES CASH EXPENDITURES FOR 2019 INCLUDING ONE-TIME RESTRUCTURING RELATED COSTS, IN RANGE OF $27 TO $29 MILLION, WITH FULL EFFECT OF SAVINGS REFLECTED IN 2020.

Compugen Q3 Loss Per Share $0.05

Nov 7 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN REPORTS THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.05.Q3 REVENUE $7.8 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.20, REVENUE VIEW $0.00 -- THOMSON REUTERS I/B/E/S.

Compugen Announces Clinical Milestone Payment In Cancer Immunotherapy Collaboration With Bayer

Sept 20 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN ANNOUNCES CLINICAL MILESTONE PAYMENT IN CANCER IMMUNOTHERAPY COLLABORATION WITH BAYER FOLLOWING DOSING OF FIRST PATIENT IN BAY 1905254 PHASE 1 TRIAL.COMPUGEN LTD - UNDER TERMS OF COLLABORATION AND LICENSE AGREEMENT, CO IS ENTITLED TO A MILESTONE PAYMENT OF $7.8 MILLION AT FIRST PATIENT DOSING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up